Novartis reports positive Q2
BASEL, Switzerland Sales and profits grew significantly for Swiss drug maker Novartis, with significant growth across divisions, according to the company’s second-quarter earnings report.
Novartis reported an 11% increase in net sales, to $11.7 billion, compared with $10.5 billion in second quarter 2009, while profits grew by 19%, to $2.4 billion, compared with $2 billion the year before.
The company’s major products mostly saw increases in sales; the cancer drug Gleevec (imatinib mesylate) had sales of $1 billion, compared with $990 million in second quarter 2009, while sales of the once-yearly osteoporosis treatment Reclast (zoledronic acid) increased from $115 million to $142 million.
Sandoz, the drug maker’s generics division, had an 11% sales increase, to $1.9 billion, compared with $1.7 billion in second quarter 2009.
Lunesta maker gets name change
MARLBOROUGH, Mass. The maker of a popular prescription sleeping pill is getting a name change.
Sepracor said Thursday that it would change its name to Sunivion Pharmaceuticals. The company, which Dainippon Sumitomo Pharma Co. acquired in October, makes the sleeping drug Lunesta (eszopiclone).
“The post-merger integration progressed very smoothly and was completed earlier than expected,” DSP president and CEO Masayo Tada said. “Therefore, in April 2010, we merged [Dainippon Sumitomo Pharma America], our other U.S. subsidiary, with and into Sepracor.”
FlavoRx launches new medicine flavor spray
COLUMBIA, Md. FlavoRx announced the launch of Yo Gabba Gabba! medicine-time flavor spray, an innovative new product designed to improve the medicine-taking experience for children and their parents.
Yo Gabba Gabba! medicine-time flavor spray is a flavored spray that coats a child’s tongue and mouth with special sugar-free, dye-free sweetening enhancers and a fun, new Dazzleberry flavor. By covering the taste buds of the tongue, the Dazzleberry-flavored liquid helps mask the bitter taste of many medications.
“With the help of Yo Gabba Gabba!, we wanted to find a way to bring home a positive and interactive medicine taking experience for both kids and parents.” said Chris Cielewich, VP sales for FlavoRx. “We’ve been improving the taste of kid’s medicine for over 15 years, and this partnership will continue our mission to enhance the medicine-time experience to deliver higher adherence rates.”